Artemisinin is highly effective against drug-resistant malarial parasites, which affects nearly half of the global population and kills >500 000 people each year. The primary cost of artemisinin is the very expensive process used to extract and purify the drug from Artemisia annua. Elimination of this apparently unnecessary step will make this potent antimalarial drug affordable to the global population living in endemic regions.
These results suggest a significant association between asymptomatic malaria and anaemia in children.
There has been a dramatic fall in the burden of malaria in Myanmar since 2005.
The burden of malaria in this birth cohort of HEU infants living in a high-transmission setting and taking daily TS prophylaxis was relatively low.
An equal number of cases were diagnosed from the private sector and government sector in the Colombo District in 2015.
From the perspective of health workers, use of intramuscular artesunate as pre-referral treatment of severe malaria cases at the health post is possible but dependent on training and availability of skilled workers.
Plasmodium vivax was detected more frequently than it was reported from the district hospital.
The universal coverage campaign of ITNs was not associated with a reduced burden of malaria among children in Malawi.
Despite improvements in inpatient malaria care, high rates of presumptive treatment for test negative children and likely over-use of injectable anti-malarial drugs were observed